Hepatitis E vaccine—Illuminating the barriers to use.

HEV study protocol: design of a cluster-randomised, blinded trial to assess the safety, immunogenicity and effectiveness of the hepatitis E vaccine HEV 239 (Hecolin) in women of childbearing age in rural Bangladesh. Barriers to use Use of vaccine in an outbreak Although the 2015 WHO position paper acknowledged that there may be special situations where HEV vaccine should be used, including outbreaks of hepatitis E, decisions regarding use of vaccine were deferred to local/national authorities. Hepatitis E vaccine - Illuminating the barriers to use HEV study protocol: design of a cluster-randomised, blinded trial to assess the safety, immunogenicity and effectiveness of the hepatitis E vaccine HEV 239 (Hecolin) in women of childbearing age in rural Bangladesh. [Extracted from the article]